Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome

Journal of Surgical Oncology

Volumn 83, Issue 2, 2003, Pages 85-93

  Iguchi, Chikage ^a   Nio, Yoshinori ^a   Itakura, Masayuki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Nodal involvement; Tumor heterogeneity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXIFLURIDINE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; TAMOXIFEN CITRATE; UFT;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 0037534031     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10243     Document Type: Article

References (36)

1. Jensen EV: Hormone dependency of breast cancer. Cancer 1981; 47:2319-2326.
2. Fisher B, Redmond C, Brown A, et al.: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-241.
3. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer, Breast Cancer Res Treat 1987;10:5-9.
4. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-1467.
5. Knight WA III, Livingston RB, Gregory EJ, et al.: Estrogen receptors as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37:4669-4671.
6. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988;15:20-25.
7. Chevallier B, Heintzmann F, Mosseri V, et al.: Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer 1988;62: 2517-2524.
8. Nomura Y, Miura S, Koyama H, et al.: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 1992;69:153-164.
9. Andersen J, Thorpe SM, King WJ, et al.: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid binding assays. Eur J Cancer 1990;26:442-449.
10. McGuire WL, Clark GM: Prognostic factors for recurrence and survival in axillar node-negative breast cancer. J Steroid Biochem 1989;34:145-148.
11. Cheung KL, Nicholson RI, Blamey RW, et al.: Selection of primary breast cancer patients for adjuvant endocrine therapy-isoestrogen receptor alone adequate? Breast Cancer Res Treat 2001;65:155-162.
12. Stierer M, Rosen H, Weber R, et al.: A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 1995;36:11-21.
13. Adami HO, Graffman S, Lindgren A, et al.: Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 1985;5:293-300.
14. Alexieva-Figussh J, Van Putten WL, Blankenstein MA, et al.: The prognostic value and relationships of patient characteristics, estrogen and progesterone receptors, and site of relapse in primary breast cancer. Cancer 1988;61:758-768.
15. Coutts AS, Leygue E, Murphy LC: Variant estrogen receptor-alpha messenger RNA expression in hormone-independent human breast cancer cells. J Mol Endocrinol 1999;23:325-336.
16. Biswas DK, Cruz AP, Pardee AB: Detection of the level of estrogen receptor and functional variants in human breast cancers by novel assays. Biotechniques 2000;29:1056-1060, 1062-1064.
17. Speirs V, Kerin MJ: Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 2000;87:405-409.
18. Mann S, Laucirica R, Carlson N, et al.: Estrogen receptor beta expression in invasive breast cancer. Human Pathol 2001;32:113- 118.
19. Nedergaard L, Haerslev T, Jacobsen GK: Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 1995;103:20-24.
20. Holdaway M, Bowditch JV: Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-485.
21. American Joint Committee on Cancer. 1997. TNM committee of the International Union Against Cancer. Staging of cancer from the manual for staging of cancer. 5th Edition.
22. Al Saati T, Clamens S, Cohne-Knafo E, et al.: Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (PER). Int J Cancer 1993;55:651-654.
23. Kobayashi S, Ito Y, Ando Y, et al.: Comparison of five different antibodies in the immunohistochemical assay of estrogen receptor alpha in human breast cancer. Breast Cancer 2000;7:136-141.
24. Lacroix M, Querton G, Hennebert P, et al.: Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunohistochemical assay, and northern blot: A comparison. Breast Cancer Res Treat 2001;67:263-271.
25. Layfield LJ, Saria EA, Conlon DH, et al.: Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: Prognostic significance. J Surg Oncol 1996;61:177-184.
26. Harvey JM, Clark GM, Osborne CK, et al.: Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
27. Rhodes A, Jasani B, Balaton AJ, et al.: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-696.
28. Fisher B, Redmond C, Fisher ER, et al.: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol 1988;6: 1076-1087.
29. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996;348:1189-1196.
30. Andersen J, Bentzen SM, Poulsen HS: Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol 1988;24:377-384.
31. Andersen J, Poulsen HS: Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989;64: 1901-1908.
32. Fidler IJ, Poste G: The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Semin Oncol 1985;12:207-221.
33. Heppner GH: Perspective in cancer research: Tumor heterogeneity. Cancer Res 1984;44:2259-2265.
34. Tanigawa N, Mizuno Y, Hashimura T, et al.: Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay. Cancer Res 1984;44:2309-2312.
35. Nio Y, Imai S, Shiraishi T, et al.: Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay. Cancer 1990;65:1273-1278.
36. Nio Y, Tamura K, Tsubono M, et al.: Antitumor chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. Ann Surg 1995;221:89-99.